PARP抑制剂与PD-1/PD-L1抑制剂在恶性肿瘤中联合应用的研究进展  

Research Progress in Combined Application of PARP Inhibitors and PD-1/PD-L1 Inhibitors in Malignant Tumors

作　　者：陈思宇 孙伟 姜永生 CHEN Siyu;SUN Wei;JIANG Yongsheng(Department of Oncology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤科,武汉430030

出　　处：《中国药学杂志》2023年第24期2235-2239,共5页Chinese Pharmaceutical Journal

摘　　要：目前,程序性死亡蛋白-1/程序性死亡配体-1(PD-1/PD-L1)抑制剂已被批准用于治疗多种实体瘤和血液系统恶性肿瘤。然而在一些肿瘤中,PD-1/PD-L1抑制剂尚未显示出显著疗效。DNA修复途径的缺陷使肿瘤细胞对多腺苷二磷酸核糖聚合酶[poly(ADP-ribose)polymerase,PARP]活性的抑制高度敏感,越来越多的临床前研究发现PARP抑制剂可以通过多种途径影响免疫系统、改变肿瘤微环境。PARP抑制剂联合PD-1/PD-L1抑制剂被认为是改善治疗效果的可行方法。笔者通过检索相关文献及临床研究资料,综述了PARP抑制剂和PD-1/PD-L1抑制剂联合应用的研究进展。At present,PD-1 and PD-L1 inhibitors have been approved for numerous solid tumors and hematological malignancies.However,PD-1 and PDL-1 inhibitors show little effect in some cancers.Owing to DNA repair deficiency,tumor cells are highly responsive to poly(ADP-ribose)polymerase(PARP)inhibition.Accumulating evidence suggests that PARP inhibitors are able to interact with the immune system and change the tumor microenvironment in a variety of ways.Thus,combination of PARP inhibitors with PD-1/PD-L1 inhibitors is known as a reasonable way to improve the efficacy.In this review,the advances of combining PD-1/PD-L1 inhibitors and PARP inhibitors in clinical studies are discussed by retrieving relevant literatures and clinical research materials.

关 键 词：多腺苷二磷酸核糖聚合酶抑制剂 程序性死亡蛋白-1/程序性死亡配体-1抑制剂 恶性肿瘤 

分 类 号：R979.1[医药卫生—药品]